Research Report Nugge丨Huaxin Securities: Paulite achieved a national layout of blood purification consumables and gave it the first “buy” rating
Paulette (300246) 2023 Interim Report Review: Continuously Optimizing Product Structure, Reducing Costs, Increasing Efficiency, and Steady Progress
Paulette (300246) 2022 Annual Report and 2023 Quarterly Report Reviews: Revenue achieved steady growth in '22 and performance in '23 is expected to reach an inflection point
Paulette (300246) 2022 Third Quarter Report Review: The Impact of the Epidemic Disturbance Weakens Product Iteration Enriches Pipelines
Paulette (300246): The time is right to lay out new medical infrastructure for two-wheel drive hemodialysis and monitoring equipment
Paulette (300246): The impact of raw material costs and exchange rates on current performance growth does not hinder long-term investment value
Paulette (300246) Quarterly report comments: the long-term development of the hemodialysis product line is becoming clearer; the decline in sales of monitors is a drag on the results of the third quarter.
Paulette (300246): 9.64% growth in the third quarter of 2017. Short-term growth slowdown does not hinder the company's long-term high growth trend.
Paulette (300246) report comments: thanks to the high growth of hemodialysis business in 17 years, H1 performance achieved a high growth of 30%.
Comment on Paulette (300246): the rapid development of hemodialysis product line leads to the sustained and rapid growth of the company's performance.
Paulette (300246) report comments: hemodialysis business continues to maintain steady growth
Comments on Paulette (300246): monitoring plate under pressure to watch the development of hemodialysis
Paulette (300246) in-depth report: seeds with large space and small market capitalization in the implementation of the whole industry chain of hemodialysis
Comments on the pre-increase of Paulette (300246): the layout of the whole industry chain of hemodialysis continues to improve and the business continues to grow at a high rate.
Paulette (300246): The hemodialysis business is progressing steadily, and interim results are expected to increase by 20%-45%
Paulette (300246): Acquisition of Corredi, a manufacturer of hemodialysis consumables in central China, breaks geographical restrictions
Paulette (300246): Continuously improving the layout of the entire hemodialysis production chain hemodialysis consumables production base, and the national layout is basically completed
Paulette (300246): The acquisition of Corredi deepens the national layout of dialysis powder in central China and is beginning to take shape
Paulette (300246): Chairman of Chunjiang Plumbing Duck Prophet “Guarantee” Initiatives to Increase Employee Sales
宝莱特(300246):董事长坚定看好公司长期发展 倡议员工“保底”增持 彰显雄心与信心
No Data